携带淋球菌诊断标志物DR-9的新共生奈瑟菌导致Roche cobas NAAT假阳性
本文报告从疑似淋球菌治疗失败患者口咽部分离出一株新型共生奈瑟菌,该菌携带淋球菌诊断标志物DR-9,导致Roche cobas CT/NG检测持续假阳性,而Aptima Combo 2检测阴性且培养未分离出淋球菌。全基因组测序证实该菌与淋球菌有部分基因组同源性并携带DR-9区域,交叉反应在cobas 4800和6800平台得到确认。研究提示口咽部共生奈瑟菌可导致NAAT假阳性,需采用替代靶标确认及加强基因组监测。
要点
- 口咽部共生奈瑟菌携带DR-9可导致cobas NAAT持续假阳性。
- 复检阳性时建议用靶向16S rRNA的AC2等替代靶标确认。
- 需对奈瑟菌进行基因组监测以评估诊断性能和耐药传播。
核心结论
- 携带淋球菌诊断标志物DR-9的新型共生奈瑟菌可导致Roche cobas NAAT假阳性,造成误诊和不必要治疗。
研究设计与样本
- 病例报告:从疑似淋球菌治疗失败患者口咽部分离共生奈瑟菌,进行全基因组测序、交叉反应验证和抗菌药物敏感性分析。
主要发现
- cobas CT/NG检测在治疗后反复阳性,AC2检测阴性,多次培养未分离出淋球菌,却回收一株共生奈瑟菌。
- 全基因组测序显示该分离株与包括淋球菌在内的多种奈瑟菌有部分基因组同源性,并携带编码DR-9的独特区域。
- 交叉反应在cobas 4800和6800平台得到确认,但靶向16S rRNA的AC2检测无交叉反应。
临床怎么用
- 口咽部标本cobas NAAT反复阳性而临床怀疑治疗失败时,应使用AC2等替代靶标确认。
- 对重复阳性的生殖道外标本应考虑确认试验,避免误诊和不必要治疗。
- 加强淋球菌和共生奈瑟菌的基因组监测,以追踪诊断性能和耐药决定因子。
局限性
- 本文为单病例报告,不能推断该共生奈瑟菌在人群中的流行率或假阳性发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neisseria gonorrhoeae (Ng), the etiologic agent of gonorrhea, is the second most reported bacterial sexually transmitted infection globally. In the USA, nucleic acid amplification tests (NAATs) are considered the gold standard for diagnosis. Although NAATs are sensitive and offer high throughput, cross-reactivity with commensal Neisseria can compromise specificity. Here, we report the isolation and characterization of a novel commensal Neisseria sp. from the oropharynx of a patient with suspected gonococcal treatment failure. An initial diagnosis was made using the Roche cobas CT/NG test on the cobas 8800 system, which repeatedly yielded positive results post-treatment. A confirmatory Aptima Combo 2 (AC2, Hologic) test was negative, and multiple culture attempts failed to isolate Ng. Instead, a commensal Neisseria strain was recovered. Whole-genome sequencing revealed this isolate shared partial genomic identity with several Neisseria spp., including Ng, and carried a distinct region encoding the gonococcal diagnostic marker DR-9, the target of cobas assays. Cross-reactivity was confirmed with the cobas 4800 and 6800 platforms, but not with the AC2 assay targeting 16S rRNA. We discuss the possible origins of the DR-9 marker on this strain as well as examine its antimicrobial susceptibility profile and genomic resistance markers. These findings highlight the potential for misdiagnosis and unnecessary treatment when commensal Neisseria species harbor Ng diagnostic targets. Our study underscores the need for genomic surveillance of Ng and commensal Neisseria, not only to monitor diagnostic performance but also to track commensals that may serve as reservoirs of antimicrobial resistance determinants and contribute to the spread of resistance.IMPORTANCEAccurate diagnosis of gonorrhea is critical for effective treatment and antimicrobial stewardship. Nucleic acid amplification tests, the mainstay of gonococcal diagnostic testing, can yield false-positive results due to genetic overlap between Neisseria gonorrhoeae and commensal Neisseria species, especially from extragenital sites like the oropharynx. Prior studies, such as Hopkins et al. (2023), have recognized this limitation and proposed supplemental tests to improve specificity for oropharyngeal specimens. Here, we describe a novel commensal Neisseria strain isolated from a patient with suspected treatment failure that harbors the gonococcal diagnostic marker DR-9. This case highlights the need for confirmatory testing using an alternate gene target in cases where repeated positive tests are obtained with extragenital specimens and demonstrates the need for improved test specificity, particularly for anatomical sites such as the pharynx, which has high commensal diversity. Enhanced molecular surveillance of commensal Neisseria populations will be vital for understanding and minimizing diagnostic cross-reactivity.
引用
- Ayala JC, Hutton SM, Cartee JC, et al. A novel commensal Neisseria species harboring the gonococcal diagnostic marker DR-9 causes false-positive Roche cobas NAAT results. J Clin Microbiol. 2025. PMID: 41258706. doi:10.1128/jcm.01022-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。